Herein, we report the results of a post hoc analysis evaluating the effect of semaglutide on levels of ALT and C‐reactive protein in subjects enrolled in two clinical trials of semaglutide treatment for obesity or type 2 diabetes, two conditions related to NASH. The gene discussed is GPT; the disease is Obesity.